Ficerafusp Alfa Shows Strong Responses in HNSCC
BOSTON, Mass., Feb. 20, 2026 — New clinical findings presented at a major oncology symposium demonstrate that ficerafusp alfa...
Breakthrough Therapy Designation
FDA Grants Breakthrough Therapy Status to Bezuclastinib in GIST
Waltham, Massachusetts & Boulder, Colorado, January 26, 2026 — Cogent Biosciences, Inc. announced that the U.S. Food and Drug...
FDA Grants Breakthrough Status to Ianalumab in Sjögren’s
Basel, January 16, 2026 — Novartis announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation...
vTv Therapeutics Strengthens Balance Sheet for Phase 3
HIGH POINT, N.C., November 6, 2025 — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company developing innovative oral...
Zenocutuzumab-zbco Earns FDA Breakthrough Therapy Status for NRG1+ Cholangiocarcinoma
LEXINGTON, Mass., October 23, 2025– Partner Therapeutics, Inc. (PTx), a fully integrated biotechnology company, announced that the U.S. Food...
Daiichi Sankyo and Merck Strengthen ADC Pipeline with FDA Nod
BASKING RIDGE, N.J. and RAHWAY, N.J., September 15, 2025 – Daiichi Sankyo and Merck (known as MSD outside the...
FDA Approves J&J’s INLEXZO™, Redefining Bladder Cancer Care
September 9, 2025 – Raritan, N.J. – In a landmark regulatory milestone, Johnson & Johnson (NYSE: JNJ) announced U.S....